Quality of life after palliative radiotherapy in non-small cell lung cancer: A prospective study

Autor: Langendijk, JA, Ten Velde, GPM, Aaronson, NK, De Jong, JMA, Muller, MJ, Wouters, EFM
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groothuis lab
Jazyk: angličtina
Rok vydání: 2000
Předmět:
Zdroj: International Journal of Radiation Oncology Biology Physics, 47(1), 149-155. ELSEVIER SCIENCE INC
ISSN: 0360-3016
Popis: Purpose: The purpose of this study was to investigate changes in respiratory symptoms and quality of life (QoL) in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy. Additionally, the correlation between the level of symptom relief and objective tumor response was investigated. Methods and Materials: Sixty-five patients were entered in this prospective study. The EORTC QLQ-C30 and EORTC QLQ-LC13 were used to investigate changes in QoL, Assessments were performed before radiotherapy and 2 weeks, 6 weeks, and 3 months after radiotherapy. Results: The QoL response rates were excellent for hemoptysis (79%); good for arm/shoulder pain (56%), chest wall pain (53%), and cough (49%); moderate for dyspnea (39%); and minimal for the general symptoms fatigue (22%) and appetite loss (11%), The QoL response rates for the five functioning scales of the QLQ-C30 varied from 35% for role functioning to 57% for emotional functioning. Global QoL improved in 37% of the cases. In general, there was a tendency for better palliation of symptoms and improvement of QoL among patients with an objective tumor response than among those without objective tumor response, which was statistically significant for dyspnea (p = 0.02) and social functioning (p = 0.04). Conclusions: This study confirms that conventional thoracic radiotherapy offers palliation of respiratory symptoms and improved QoL in a substantial proportion of patients with locally advanced and metastatic NSCLC, Tumor reduction is only one of the mechanisms by which palliation of symptoms and improvement of QoL is achieved. (C) 2000 Elsevier Science Inc.
Databáze: OpenAIRE